Purple Biotech (PPBT) Accounts Payables (2014 - 2026)

Purple Biotech (PPBT) has reported Accounts Payables for 13 consecutive years, with $487000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Accounts Payables fell 27.2% year-over-year to $487000.0 in Q2 2026; TTM through Jun 2026 was $487000.0, a 27.2% decrease from a year earlier, with the FY2025 full-year figure at $2.1 million, up 42.27% from the prior year.
• Accounts Payables was $487000.0 for Q2 2026 at Purple Biotech, down from $843000.0 in the prior quarter.
• Over five years, Accounts Payables peaked at $3.5 million in Q4 2023 and troughed at $487000.0 in Q2 2026.
• A 5-year average of $1.9 million and a median of $1.8 million in 2022 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables surged 93.51% in 2024 and slumped 78.01% in 2025, its largest moves.
• Over 5 years, Accounts Payables stood at $2.1 million in 2022, then surged by 65.67% to $3.5 million in 2023, then plunged by 58.81% to $1.5 million in 2024, then jumped by 42.27% to $2.1 million in 2025, then sank by 76.47% to $487000.0 in 2026.
• The last three Accounts Payables figures came in at $487000.0 (Q2 2026), $843000.0 (Q1 2026), and $2.1 million (Q4 2025), per Business Quant data.